Sandostatin, Mycapssa(octreotide)
Mycapssa, Sandostatin (octreotide) is a protein pharmaceutical. Octreotide was first approved as Sandostatin on 1988-10-21. It is used to treat acromegaly, adenoma, diarrhea, pancreatic neoplasms, and pituitary neoplasms in the USA. It has been approved in Europe to treat acromegaly. The pharmaceutical is active against somatostatin receptor type 2. In addition, it is known to target somatostatin receptor type 3 and somatostatin receptor type 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Bynfezia, Mycapssa, Octreotide, Sandostatin (discontinued: Octreotide, Sandostatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Octreotide acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MYCAPSSA | Chiesi Farmaceutici | N-208232 RX | 2020-06-26 | 1 products, RLD, RS |
| SANDOSTATIN | Novartis | N-019667 RX | 1988-10-21 | 3 products, RLD, RS |
| SANDOSTATIN LAR | Novartis | N-021008 RX | 1998-11-25 | 3 products, RLD, RS |
| BYNFEZIA PEN | Sun Pharmaceutical Industries | N-213224 RX | 2024-09-27 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bynfezia pen | New Drug Application | 2025-02-21 |
| mycapssa | New Drug Application | 2024-08-21 |
| octreotide | ANDA | 2024-05-23 |
| octreotide acetate | ANDA | 2025-05-13 |
| octreotide octreotide | ANDA | 2019-09-12 |
| sandostatin | New Drug Application | 2025-01-21 |
| sandostatin lar depot | New Drug Application | 2024-07-11 |
| sandostatin lar depot sandostatin lar depot demonstration | New Drug Application | 2014-05-19 |
| sandostatin lar depot sandostatin lar depot demonstration kit | New Drug Application | 2016-07-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pancreatic neoplasms | EFO_0003860 | D010190 | C25 |
| diarrhea | — | D003967 | R19.7 |
| pituitary neoplasms | — | D010911 | — |
| adenoma | — | D000236 | — |
| acromegaly | — | D000172 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
OCTREOTIDE ACETATE, MYCAPSSA, AMRYT | |||
| 2023-06-26 | NP | ||
Patent Expiration
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01C: Hypothalamic hormones
— H01CB: Somatostatin and analogues
— H01CB02: Octreotide
V: Various drug classes in atc
— V09: Diagnostic radiopharmaceuticals
— V09I: Tumour detection radiopharmaceuticals
— V09IA: Technetium (99mtc) compounds
— V09IA07: Technetium (99mtc) hynic-octreotide
Clinical
Clinical Trials
302 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 14 | 33 | 15 | 3 | 10 | 69 |
| Acromegaly | D000172 | — | — | 5 | 11 | 17 | 17 | 9 | 58 |
| Neoplasms | D009369 | — | C80 | 10 | 11 | 6 | 2 | 3 | 29 |
| Carcinoid tumor | D002276 | — | D3A.00 | 9 | 10 | 6 | 1 | — | 23 |
| Syndrome | D013577 | — | — | 2 | 8 | 4 | 3 | 4 | 19 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 2 | 2 | 4 | 8 | 16 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | 3 | 1 | 5 | 6 | 14 |
| Malignant carcinoid syndrome | D008303 | — | E34.0 | 4 | 6 | 3 | 1 | — | 13 |
| Diarrhea | D003967 | — | R19.7 | — | 3 | 5 | 1 | 3 | 12 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 4 | 1 | — | 3 | 4 | 12 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 7 | 3 | — | 2 | 13 |
| Carcinoma | D002277 | — | C80.0 | 2 | 8 | 3 | — | — | 12 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 2 | 2 | — | 3 | 8 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 3 | 3 | 2 | — | 1 | 7 |
| Autosomal dominant polycystic kidney | D016891 | EFO_1001496 | Q61.2 | — | 4 | 4 | — | 1 | 7 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 3 | 3 | — | 1 | 6 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 3 | 3 | — | 1 | 6 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 3 | 1 | — | — | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 2 | — | 2 | 5 |
| Intestinal neoplasms | D007414 | — | C26.0 | 1 | 1 | 2 | — | 1 | 5 |
Show 29 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Islet cell adenoma | D007516 | EFO_0007331 | D13.7 | 2 | 6 | — | — | 2 | 10 |
| Neuroendocrine carcinoma | D018278 | — | — | 2 | 6 | — | — | — | 8 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 3 | 6 | — | — | — | 7 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | 2 | 5 | — | — | 1 | 7 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 3 | 4 | — | — | — | 7 |
| Recurrence | D012008 | — | — | 1 | 3 | — | — | 2 | 6 |
| Medulloblastoma | D008527 | — | — | 1 | 4 | — | — | 1 | 5 |
| Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | 4 | 5 |
| Pheochromocytoma | D010673 | — | — | 2 | 2 | — | — | — | 4 |
| Islet cell carcinoma | D018273 | — | C25.4 | 1 | 3 | — | — | — | 4 |
Show 45 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 5 | — | — | — | 2 | 7 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 3 | — | — | — | 1 | 4 |
| Fatty liver | D005234 | EFO_0003934 | — | 3 | — | — | — | 1 | 4 |
| Central nervous system neoplasms | D016543 | — | — | 3 | — | — | — | — | 3 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 3 | — | — | — | — | 3 |
| Nervous system neoplasms | D009423 | — | — | 2 | — | — | — | — | 2 |
| Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | 2 | — | — | — | — | 2 |
| Glucagonoma | D005935 | — | — | 2 | — | — | — | — | 2 |
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | — | — | — | — | 1 |
Show 22 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Weight loss | D015431 | — | — | — | — | — | — | 3 | 3 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 2 | 2 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 2 | 2 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 2 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 2 | 2 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | — | — | 2 | 2 |
| Myocarditis | D009205 | — | I51.4 | — | — | — | — | 1 | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | — | 1 | 1 |
| Glioma | D005910 | EFO_0000520 | — | — | — | — | — | 1 | 1 |
Show 41 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Octreotide |
| INN | octreotide |
| Description | Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer, and binds predominantly to the somatostatin receptors SSTR2 and SSTR5.
|
| Classification | Protein |
| Drug class | peptides: inhibition of growth hormone release |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 83150-76-9 |
| RxCUI | 7617 |
| ChEMBL ID | CHEMBL1680 |
| ChEBI ID | — |
| PubChem CID | 448601 |
| DrugBank | DB00104 |
| UNII ID | RWM8CCW8GP (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Sandostatin – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Mycapssa – Amryt Pharma
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Octreotide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 20,355 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
35,498 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use